Clinical and molecular heterogeneity are common features of human disease. Understanding the basis for heterogeneity has led to major advances in therapy for many cancers and pulmonary diseases such as cystic fibrosis and asthma. Although heterogeneity of risk factors, disease severity and outcomes in survivors are common features of the Acute Respiratory Distress Syndrome (ARDS), many challenges exist in understanding the clinical and molecular basis for disease heterogeneity and using heterogeneity to tailor therapy for individual patients. This report summarizes the proceedings of the 2021 Aspen Lung Conference, which was organized to review key issues related to understanding clinical and molecular heterogeneity in ARDS. The goals were to review new information about ARDS phenotypes, to explore multicellular and multisystem mechanisms responsible for heterogeneity and to review how best to account for clinical and molecular heterogeneity in clinical trial design and assessment of outcomes. The report concludes with recommendations for future research to understand the clinical and basic mechanisms underlying heterogeneity in ARDS in order to advance development of new treatments for this life-threatening critical illness.
- Martin, T. R.
- Zemans, R. L.
- Ware, L. B.
- Schmidt, E. P.
- Riches, D. W. H.
- Bastarache, L.
- Calfee, C. S.
- Desai, T. J.
- Herold, S.
- Hough, C. L.
- Looney, M. R.
- Matthay, M. A.
- Meyer, N.
- Parikh, S. M.
- Stevens, T.
- Thompson, B. T.
Keywords
- Ards
- Biological mechanisms
- Clinical trials
- Critical Care